Results 71 to 80 of about 28,958 (244)

Venous Thromboembolism in Hematologic Malignancies: Incidence, Risk Factors, and the Role of Direct Oral Anticoagulants

European Journal of Haematology, EarlyView.
ABSTRACT Thrombotic events, particularly venous thromboembolism (VTE), are a significant source of morbidity and mortality among patients with hematologic malignancies. These patients face unique challenges due to treatment‐related complications such as thrombocytopenia, coagulopathy, and heightened bleeding risk.
Mario Biglietto, Silvia Sorella, Erminia Baldacci, Massimo Breccia, Sabina Chiaretti, Marcello Capriata, Livia Donzelli, Gianna Maria D'Elia, Salvatore Giacomo Morano, Ilaria Del Giudice, Maurizio Martelli, Cristina Santoro, Antonio Chistolini   +12 more
wiley   +1 more source

Dabigatran ameliorates airway smooth muscle remodeling in asthma by modulating Yes‐associated protein

Journal of Cellular and Molecular Medicine, 2020
Accumulating evidence indicates that thrombin, the major effector of the coagulation cascade, plays an important role in the pathogenesis of asthma. Interestingly, dabigatran, a drug used in clinical anticoagulation, directly inhibits thrombin activity ...
Zhenan Deng, Haojun Xie, Weiying Cheng, Meihong Zhang, Jie Liu, Yating Huo, Y. Liao, Yuanxiong Cheng   +7 more
semanticscholar   +1 more source

Do We Really Know How to Manage Anticoagulated Patients for Periodontal Nonsurgical Therapy? An Observational Cohort Study

International Journal of Dental Hygiene, EarlyView.
ABSTRACT Objectives The aim of this work is to assess and compare the impact of direct oral anticoagulants (DOACs) versus vitamin K antagonists (VKA) during and immediately after periodontal nonsurgical therapy. Materials and Methods A prospective observational cohort study was conducted with patients who presented a history of cardiovascular disease ...
F. Berton, A. Rapani, F. Costantinides, V. Nicolin, D. Cuhureanu, R. Di Lenarda   +5 more
wiley   +1 more source

Dabigatran experience in primary and secondary prevention of cardioembolic stroke

Неврология, нейропсихиатрия, психосоматика, 2013
The review of novel oral anticoagulants (dabigatran, rivaroxaban and apixaban) in stroke prevention and also own data of administration of dabigatran in primary and secondary prevention of ischemic stroke in 45 patients with cerebrovascular diseases are ...
Maksim Alekseyevich Domashenko, M Yu Maksimova, D Z Korobkova, M E Gafarova   +3 more
doaj   +1 more source

Design and Implementation of an Automated Interpretation Algorithm for Lupus Anticoagulant Functional Testing

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Introduction Lupus anticoagulant (LA) testing is essential, albeit complex, in the laboratory diagnosis of antiphospholipid syndrome (APS). Given the multi‐step workflow and the variability introduced by anticoagulant therapy, reagent differences, and interpretive approaches, result interpretation requires expert evaluation.
Chiara Novelli, Arianna Gatti, Flora Ierna, Elena Riccardi, Irene Cuppari   +4 more
wiley   +1 more source

Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry

Therapeutic Advances in Neurological Disorders, 2014
Background: There are growing concerns for the side effects of dabigatran etexilate (dabigatran), including higher incidence of dyspepsia and gastrointestinal bleeding.
Georgios Tsivgoulis, Christos Krogias, Kara A. Sands, Vijay K. Sharma, Aristeidis H. Katsanos, Konstantinos Vadikolias, Sokratis G. Papageorgiou, Ioannis Heliopoulos, Harn Shiue, Athina Mitsoglou, Chrissoula Liantinioti, Dimitrios Athanasiadis, Sotirios Giannopoulos, Charitomeni Piperidou, Konstantinos Voumvourakis, Andrei V. Alexandrov   +15 more
doaj   +1 more source

Geographical variability in dabigatran dosing within New Zealand

Internal Medicine Journal, EarlyView.
Abstract Dabigatran etexilate is an oral anticoagulant with increased risk of bleeding at high drug exposure. It is available in three capsule strengths (75, 110 and 150 mg). We analysed New Zealand dispensing data from 2019 to 2023 to compare use between health districts. Overall use was similar across districts.
Liam T. Berryman, Paul K. L. Chin, Lorna J. Pairman, Milan Sundermann, Matthew Doogue   +4 more
wiley   +1 more source

Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation.

PLoS ONE, 2012
BackgroundDabigatran is associated with lower rate of stroke comparing to warfarin when anticoagulation control is sub-optimal. Genotype-guided warfarin dosing and management may improve patient-time in target range (TTR) and therefore affect the cost ...
Joyce H S You, Kia K N Tsui, Raymond S M Wong, Gergory Cheng   +3 more
doaj   +1 more source

Zero‐Contrast Versus Contrast‐Guided Left Atrial Appendage Occlusion: A Comparative Analysis of Procedural and Long‐Term Outcomes

Journal of Cardiovascular Electrophysiology, EarlyView.
Zero‐contrast left atrial appendage occlusion yielded high procedural success and similar periprocedural adverse event rates compared to the contrast‐guided approach. At 45‐day follow‐up, successful LAA closure (defined as peri‐device leak ≤ 5 mm) and device‐related thrombus rates were similar.
Joe Demian, Andrew LaCombe, Arwa Younis, Mohamed Kanj, Walid I. Saliba, Pasquale Santangeli, Chadi Tabaja, Ioan Liuba, Bryan Baranowski, Tyler L. Taigen, Mandeep Bhargava, Oussama M. Wazni, Ayman A. Hussein   +12 more
wiley   +1 more source

Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment

Vascular Health and Risk Management, 2013
Andreas Clemens,1 Mandy Fraessdorf,2 Jeffrey Friedman31Corporate Division Medicine, TA Cardiovascular, 2Medical Data Services, Boehringer Ingelheim GmbH & Co KG, Ingelheim am Rhein, Germany; 3Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT ...
Clemens A, Fraessdorf M, Friedman J
doaj